Morgan Stanley raised the firm’s price target on Labcorp (LH) to $306 from $283 and keeps an Overweight rating on the shares. Organic volume growth and “impressive” Biopharma experience buoyed shares despite high expectations into the earnings report, the analyst noted. Heightened utilization expectations are “encouraging” into the second half, the analyst added in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Positive Outlook for Labcorp Holdings: Buy Rating Justified by Strong Future Prospects and Strategic Growth Initiatives
- Labcorp Reports Strong Q2 2025 Results, Raises Guidance
- Labcorp Holdings Reports Strong Growth and Raises Guidance
- Labcorp Holdings: Strong Financial Performance and Promising Outlook Justify Buy Rating
- Labcorp price target raised to $300 from $290 at Jefferies